| 1 | ONCSSF6 ;Hines OIFO/GWB - SITE-SPECIFIC FACTOR 6 (165.5,44.6) ;11/20/03 | 
|---|
| 2 | ;;2.11;ONCOLOGY;**40**;Mar 07, 1995 | 
|---|
| 3 | ; | 
|---|
| 4 | ;SITE-SPECIFIC FACTOR 6 (165.5,44.6) | 
|---|
| 5 | SSF6IT ;INPUT TRANSFORM | 
|---|
| 6 | ; | 
|---|
| 7 | S PS=$P($G(^ONCO(165.5,D0,2)),U,1) | 
|---|
| 8 | I PS="" K X W "  No PRIMARY SITE defined for this primary" Q | 
|---|
| 9 | S MO=$$HIST^ONCFUNC(D0) | 
|---|
| 10 | ; | 
|---|
| 11 | S SSFIEN=$S($D(^ONCO(164.52,"C",PS_"-6")):$O(^ONCO(164.52,"C",PS_"-6",0)),1:1) | 
|---|
| 12 | ; | 
|---|
| 13 | ;Malignant Melanoma of Skin, Vulva, Penis, Scrotum | 
|---|
| 14 | I $$MELANOMA^ONCOU55(D0) D | 
|---|
| 15 | .S MELIEN=$O(^ONCO(164.52,"B","LDH",0)) | 
|---|
| 16 | .I $E(PS,3,4)=44 S SSFIEN=MELIEN Q | 
|---|
| 17 | .I $E(PS,3,4)=51 S SSFIEN=MELIEN Q | 
|---|
| 18 | .I $E(PS,3,4)=60 S SSFIEN=MELIEN Q | 
|---|
| 19 | .I PS=67632 S SSFIEN=MELIEN Q | 
|---|
| 20 | ; | 
|---|
| 21 | ;Hodgkin and Non-Hodgkin Lymphomas of All Sites | 
|---|
| 22 | I $$LYMPHOMA^ONCFUNC(D0) S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0)) | 
|---|
| 23 | ; | 
|---|
| 24 | ;Mycosis Fungoides and Sezary Disease of Skin, Vulva, Penis, Scrotum | 
|---|
| 25 | ;Kaposi Sarcoma of All Sites | 
|---|
| 26 | I (MO=97003)!(MO=97013)!($E(MO,1,4)=9140) S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0)) | 
|---|
| 27 | ; | 
|---|
| 28 | ;Hematopoietic, Reticuloendothelial, Immunoproliferative, and | 
|---|
| 29 | ;Myeloproliferative Neoplasms | 
|---|
| 30 | I (MO'<97310)&(MO'>99899) S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0)) | 
|---|
| 31 | ; | 
|---|
| 32 | ;Retinoblastoma | 
|---|
| 33 | I $E(MO,1,3)=951 S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0)) | 
|---|
| 34 | ; | 
|---|
| 35 | ;Prostate | 
|---|
| 36 | I PS=67619,+X>1,+X<11 D  G ITEX | 
|---|
| 37 | .I X'?3N D  K X Q | 
|---|
| 38 | ..I X?1N W !!,"     For ",X," enter 00",X | 
|---|
| 39 | ..I X?2N W !!,"     For ",X," enter 0",X | 
|---|
| 40 | ; | 
|---|
| 41 | I '$D(^ONCO(164.52,SSFIEN,1,"B",X)) K X Q | 
|---|
| 42 | S SSF=$O(^ONCO(164.52,SSFIEN,1,"B",X,0)) | 
|---|
| 43 | W "  ",$P(^ONCO(164.52,SSFIEN,1,SSF,0),U,2) | 
|---|
| 44 | ITEX K PS,SSFIEN,SSF,MO,MELING Q | 
|---|
| 45 | ; | 
|---|
| 46 | SSF6OT ;OUTPUT TRANSFORM | 
|---|
| 47 | ; | 
|---|
| 48 | S PS=$P($G(^ONCO(165.5,D0,2)),U,1) | 
|---|
| 49 | Q:PS="" | 
|---|
| 50 | S MO=$$HIST^ONCFUNC(D0) | 
|---|
| 51 | ; | 
|---|
| 52 | S SSFIEN=$S($D(^ONCO(164.52,"C",PS_"-6")):$O(^ONCO(164.52,"C",PS_"-6",0)),1:1) | 
|---|
| 53 | ; | 
|---|
| 54 | ;Malignant Melanoma of Skin, Vulva, Penis, Scrotum | 
|---|
| 55 | I $$MELANOMA^ONCOU55(D0) D | 
|---|
| 56 | .S MELIEN=$O(^ONCO(164.52,"B","LDH",0)) | 
|---|
| 57 | .I $E(PS,3,4)=44 S SSFIEN=MELIEN Q | 
|---|
| 58 | .I $E(PS,3,4)=51 S SSFIEN=MELIEN Q | 
|---|
| 59 | .I $E(PS,3,4)=60 S SSFIEN=MELIEN Q | 
|---|
| 60 | .I PS=67632 S SSFIEN=MELIEN Q | 
|---|
| 61 | ; | 
|---|
| 62 | ;Hodgkin and Non-Hodgkin Lymphomas of All Sites | 
|---|
| 63 | I $$LYMPHOMA^ONCFUNC(D0) S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0)) | 
|---|
| 64 | ; | 
|---|
| 65 | ;Mycosis Fungoides and Sezary Disease of Skin, Vulva, Penis, Scrotum | 
|---|
| 66 | ;Kaposi Sarcoma of All Sites | 
|---|
| 67 | I (MO=97003)!(MO=97013)!($E(MO,1,4)=9140) S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0)) | 
|---|
| 68 | ; | 
|---|
| 69 | ;Hematopoietic, Reticuloendothelial, Immunoproliferative, and | 
|---|
| 70 | I (MO'<97310)&(MO'>99899) S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0)) | 
|---|
| 71 | ; | 
|---|
| 72 | ;Retinoblastoma | 
|---|
| 73 | I $E(MO,1,3)=951 S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0)) | 
|---|
| 74 | ; | 
|---|
| 75 | ;Prostate | 
|---|
| 76 | I PS=67619,+Y>1,+Y<11 G OTEX | 
|---|
| 77 | ; | 
|---|
| 78 | S SSF=$O(^ONCO(164.52,SSFIEN,1,"B",Y,0)) I SSF="" G OTEX | 
|---|
| 79 | S Y=$P($G(^ONCO(164.52,SSFIEN,1,SSF,0)),U,2) | 
|---|
| 80 | OTEX K PS,SSFIEN,SSF,MO Q | 
|---|
| 81 | ; | 
|---|
| 82 | SSF6HP ;HELP | 
|---|
| 83 | ; | 
|---|
| 84 | S PS=$P($G(^ONCO(165.5,D0,2)),U,1) | 
|---|
| 85 | Q:PS="" | 
|---|
| 86 | S MO=$$HIST^ONCFUNC(D0) | 
|---|
| 87 | ; | 
|---|
| 88 | S SSFIEN=$S($D(^ONCO(164.52,"C",PS_"-6")):$O(^ONCO(164.52,"C",PS_"-6",0)),1:1) | 
|---|
| 89 | ; | 
|---|
| 90 | ;Malignant Melanoma of Skin, Vulva, Penis, Scrotum | 
|---|
| 91 | I $$MELANOMA^ONCOU55(D0) D | 
|---|
| 92 | .S MELIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0)) | 
|---|
| 93 | .I $E(PS,3,4)=44 S SSFIEN=MELIEN Q | 
|---|
| 94 | .I $E(PS,3,4)=51 S SSFIEN=MELIEN Q | 
|---|
| 95 | .I $E(PS,3,4)=60 S SSFIEN=MELIEN Q | 
|---|
| 96 | .I PS=67632 S SSFIEN=MELIEN Q | 
|---|
| 97 | ; | 
|---|
| 98 | ;Hodgkin and Non-Hodgkin Lymphomas of All Sites | 
|---|
| 99 | I $$LYMPHOMA^ONCFUNC(D0) S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0)) | 
|---|
| 100 | ; | 
|---|
| 101 | ;Mycosis Fungoides and Sezary Disease of Skin, Vulva, Penis, Scrotum | 
|---|
| 102 | ;Kaposi Sarcoma of All Sites | 
|---|
| 103 | I (MO=97003)!(MO=97013)!($E(MO,1,4)=9140) S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0)) | 
|---|
| 104 | ; | 
|---|
| 105 | ;Hematopoietic, Reticuloendothelial, Immunoproliferative, and | 
|---|
| 106 | I (MO'<97310)&(MO'>99899) S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0)) | 
|---|
| 107 | ; | 
|---|
| 108 | ;Retinoblastoma | 
|---|
| 109 | I $E(MO,1,3)=951 S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0)) | 
|---|
| 110 | ; | 
|---|
| 111 | W !," SITE-SPECIFIC FACTOR 6 for " D | 
|---|
| 112 | .I MO=97003 W "MYCOSIS FUNGOIDES of ",$P(^ONCO(164,PS,0),U,1)," (",$P(^ONCO(164,PS,0),U,2),")" Q | 
|---|
| 113 | .I MO=97013 W "SEZARY SYNDROME of ",$P(^ONCO(164,PS,0),U,1)," (",$P(^ONCO(164,PS,0),U,2),")" Q | 
|---|
| 114 | .I $E(MO,1,3)=951 W "RETINOBLASTOMA of ",$P(^ONCO(164,PS,0),U,1)," (",$P(^ONCO(164,PS,0),U,2),")" Q | 
|---|
| 115 | .I $$MELANOMA^ONCOU55(D0),($E(PS,3,4)=44)!($E(PS,3,4)=51)!($E(PS,3,4)=60)!(PS=67632)!($E(PS,3,4)=69) W "MALIGNANT MELANOMA of ",$P(^ONCO(164,PS,0),U,1)," (",$P(^ONCO(164,PS,0),U,2),")" Q | 
|---|
| 116 | .I $E(MO,1,4)=9140 W "KAPOSI SARCOMA of ALL SITES" Q | 
|---|
| 117 | .I $$LYMPHOMA^ONCFUNC(D0) W "HODGKIN AND NON-HODGKIN LYMPHOMAS of ALL SITES" Q | 
|---|
| 118 | .I (MO'<97310)&(MO'>99899) W $P(^ONCO(169.3,MO,0),U,1)," (",$P(^ONCO(169.3,MO,0),U,2),")" Q | 
|---|
| 119 | .W $P(^ONCO(164,PS,0),U,1)," (",$P(^ONCO(164,PS,0),U,2),")" | 
|---|
| 120 | W !," ",$P(^ONCO(164.52,SSFIEN,0),U,1) | 
|---|
| 121 | ;S SSF=0 F  S SSF=$O(^ONCO(164.52,SSFIEN,1,SSF)) Q:SSF'>0  D | 
|---|
| 122 | ;.S TAB=6 | 
|---|
| 123 | ;.I ($P(^ONCO(164.52,SSFIEN,0),U,1)="GLEASON'S SCORE") S TAB=10 | 
|---|
| 124 | ;.W " ",$P(^ONCO(164.52,SSFIEN,1,SSF,0),U,1),?TAB,$P(^ONCO(164.52,SSFIEN,1,SSF,0),U,2),! | 
|---|
| 125 | K PS,SSFIEN,SSF,MO Q | 
|---|